WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2025. "The Viridian team continues to deliver strong results, highlighted by the successful submission of our BLA for veligrotug, completing enrollment in both pivotal c. ...

My hometown of Baltimore was the first city to install gas street lights in 1816 in an effort to curb crime. More cities quickly followed suit.  By the turn of the century, every evening at dusk, lamplighters walked the streets with their ladders and torches, igniting gas lamps one by one. Twenty years later, electric streetlights became more commonplace, and lamplighters became more or less an extinct species.By completing this form, you agree to receive marketing communications from PYMNTS and to the shar ...

Core Insights - Precision Concepts International (PCI) has acquired Comar, creating a larger rigid packaging platform to serve consumer and healthcare sectors [1][4] - The financial details of the acquisition were not disclosed, but it is part of The Sterling Group's strategy to enhance its portfolio [1][2] - The combined entity will benefit from increased geographic, customer, and end market diversification, positioning itself as a leader in specialty packaging [4] Company Overview - PCI, based in Huntersville, North Carolina, specializes in rigid packaging and serves small to mid-sized brands across personal care, household, and food and beverage categories [2][3] - Comar, established in 1949, produces rigid packaging and plastic medical components, operating nine sites in the US, along with locations in Puerto Rico and Ireland [1][4] - PCI operates nine manufacturing plants across Canada, the US, and Costa Rica, employing approximately 1,200 people [3] Strategic Implications - The acquisition is expected to enhance PCI's capabilities in providing industry-leading rigid packaging solutions and exceptional service [3] - PCI's CEO emphasized that the merger will allow for a broader range of products and services, delivering more value to customers [3] - The Sterling Group has a history of backing 76 platform buyouts and multiple add-on transactions, with a total deal value exceeding $25 billion [2]

Last week saw a big swing in mortgage interest rates, and that took a toll on demand. Total mortgage application volume fell 1.9% compared with the previous week, according to the Mortgage Bankers Association's seasonally adjusted index.For the week, the average contract interest rate for 30-year fixed-rate mortgages with conforming loan balances, $806,500 or less, increased to 6.31% from 6.30% for loans with a 20% down payment. That was the weekly average, but rates actually fell to the lowest level in ove ...

Accessibility StatementSkip Navigation CARMEL, Ind., Nov. 5, 2025 /PRNewswire/ -- OPENLANE, Inc. (NYSE: KAR), today reported its third quarter financial results for the period ended September 30, 2025. "OPENLANE's strategy — and the investments we've made to accelerate it — produced another strong quarter of organic growth and profitability, including 8% consolidated revenue growth and $87 million in Adjusted EBITDA," said Peter Kelly, CEO of OPENLANE. "We grew dealer-to-dealer volumes by 14%, significantly ...

MISSISSAUGA, Ontario, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is addressing a cybersecurity incident relating to a ransomware attack that has had no impact on operations but involved the theft of data. Microbix is actively addressing the incident, which highlights the importance of the Company’s ongoing program to strengthen its cybersecurity. An international hacker group, respon ...

BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in joint preservation and regenerative solutions, announced that it filed the third and final module of its Premarket Approval application (PMA) for Hyalofast—its resorbable, hyaluronic acid-based scaffold used with autologous bone marrow aspirate concentrate (BMAC) for treating articular cartilage defects in the knee. The Company also reported results from its U.S. pivotal Phase III FastTRACK clinical ...

ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study; Data mark first robust demonstration of oral OX2R agonist addressing wakefulness needs of patients across all three indications; Expect to initiate registrational program in Q1 2026ORX142: Phase 1 data support highly differentiated profile; Expect to initiate patient studies in Q1 2026 ORX489: Advancing in IND-en ...

KSI-101 is novel, potent and high strength (100 mg/mL) antibody-based investigational therapy with a bispecific mechanism of action targeting both interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF). Week 20 Data Highlights from Phase 1b APEX Study in Patients with Macular Edema Secondary to Inflammation – Baseline to Week 20 (Patients dosed at Weeks 0, 4, 8 and 12) Dose Level Accessibility StatementSkip Navigation PALO ALTO, Calif., Nov. 5, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: ...

 Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in the first half of 2026 $118 million in cash supports operations into first half of 2028, through expected proof-of-concept clinical readouts for both programs SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) ...